Allora Health Inc., the women's healthcare startup known as Evvy, said it has raised $40 million in Series B funding to expand its precision diagnostics and care platform. Catalio Capital Management led the round, joined by new investors the U.S. Fertility Innovation Fund, Rethink Impact, Muse Capital and Alumni Ventures. Existing backers LabCorp Venture Fund, General Catalyst and Left Lane Capital also participated.
Evvy markets an at-home testing kit built on metagenomic sequencing. A patient takes a swab, and the resulting biological data is analyzed by a machine learning engine called EvvyAI, which matches the patient with a personalized prescription treatment plan. The company said EvvyAI is designed to improve as it learns from each new test, and that it has spent more than five years assembling what co-founder and Chief Executive Priyanka Jain described as the world's largest clinical-grade dataset on the vaginal microbiome and women's health outcomes.
Jain attributed the gap in women's healthcare to the exclusion of women from most clinical trials of new drugs until 1993, leaving roughly 30 years of research data on female biology. She said women were long treated as small men in medical research, erasing differences that extend to the cellular level, and that this has produced misdiagnosis rates above 50% for some conditions and a recurrence rate of more than 60% for common vaginal symptoms. Jain said patients are frequently told their symptoms are unexplained when the underlying issue is that medicine was not built to measure female biology.
Evvy pointed to bacterial vaginosis as an example of what its approach can deliver. Through microbiome analysis, the company said it identified six distinct BV subtypes, showing that patients who look similar under traditional diagnostic criteria can differ in their biomes, recurrence patterns and treatment responses. Licensed clinicians using EvvyAI reported diagnosing more than 90% of symptomatic patients and a 50% reduction in recurrence of conditions such as BV, according to the company.
The startup said its technology has reached more than 100,000 patients and 3,000 medical practitioners. Its dataset has been cited in 13 peer-reviewed publications and has supported the discovery of new bacterial subtypes and hundreds of previously uncatalogued vaginal microbiome genomes, the company said.
Evvy said the new funding will validate a next generation of AI-enabled diagnostic and care models covering a broader range of women's health conditions, with fertility as its first target. Jain said the vaginal microbiome is one actionable biological signal among many in fertility care, and that the company plans to share more findings in that area later this year. Catalio Capital Managing Partner Jacob Vogelstein said the combination of proprietary data, clinical evidence and a growing biomarker discovery engine creates a new foundation for precision women's healthcare.
More company and startup news from TechManNews.
